|Articles|January 1, 1998

A Managed Care Appraisal of Atypical Agents in the Treatment of Psychoses
Volume 4
Issue 1 Suppl

Atypical Antipsychotics and Formulary Decisions

Author(s)William M. Glazer, MD

Download PDF: Atypical Antipsychotics and Formulary Decisions

Articles in this issue

over 28 years ago

Article

Common Treatment Goals: Switching Antipsychotics

over 28 years ago

Article

Antipsychotics : Present and Future

over 28 years ago

Article

Atypical Antipsychotics in the Managed Care Era

over 28 years ago

Article

CME Quiz

over 28 years ago

Article

Selected Abstracts

over 28 years ago

Article

Bibliography

over 28 years ago

Article

Participating Faculty

over 28 years ago

Article

Introduction - The Routine Use of Atypical Antipsychotics

over 28 years ago

Article

Chronic Ambulatory Outpatients and Four-Vector Management

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Atypical Antipsychotics and Formulary Decisions

Articles in this issue

Related Content

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Trending on AJMC

GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale

ACA Enrollment Erosion Deepens After Open Enrollment Ends

FDA Approves Tocilizumab-bavi for CAR-T-Induced CRS, Pediatric COVID-19

Shields Health Solutions Partners With Baptist Health on Specialty Pharmacy

AI Model Challenges Genomic Classifiers in Early Breast Cancer Risk Stratification: Nancy Lin, MD